What Semax can actually do for post-concussion recovery

Post-concussion syndrome does not run on a normal healing clock. Most bumps and bruises settle in a couple of weeks. A concussion can leave someone foggy, light-sensitive, and off their emotional baseline for months, and by week six or eight people go looking for anything that might move the recovery along, including Semax. Short answer: Semax has a real mechanistic case and a decades-long Russian clinical record in brain injury and stroke recovery, but there is no dedicated human trial in concussion specifically, so using it here means extrapolating from adjacent evidence, not reading off a study built for this exact question.

I get this question a lot from the peptide-forum crowd, usually from someone three or four months out from a head injury who has already been through the standard concussion protocol and is still foggy. It is a fair question. Semax's original clinical use is stroke and TBI recovery, and a lot of what makes it interesting there maps directly onto what a concussed brain is actually dealing with.

What a concussed brain is dealing with, and why Semax comes up

A concussion is a wave of stretched axons, a burst of inflammatory signaling, and a temporary disruption to the networks that keep your attention, mood, and short-term memory running smoothly, and most of that never shows up on a scan. The default-mode network, the set of brain regions that stay active when you are resting and thinking about nothing in particular, tends to get knocked off its normal rhythm after a head injury, and that disruption tracks pretty closely with how foggy and unfocused people feel.

Semax's mechanism lines up with that picture more than most cognitive peptides do. It binds MC4 and MC3 melanocortin receptors in the hippocampus and prefrontal cortex, and from there it drives direct transcriptional upregulation of BDNF and NGF, the two growth factors most responsible for repairing and rewiring neurons after injury. In an fMRI study, Semax increased default-mode-network volume in the medial frontal cortex compared with placebo, and a follow-up study found Semax produces measurable shifts in amygdala and prefrontal connectivity, the same emotional-regulation circuitry that gets tangled up when someone develops post-concussion anxiety or irritability. That is stroke and connectivity data, and it points to a real mechanistic overlap with what happens after a concussion, which is why the compound keeps coming up in brain-injury conversations.

What the Semax evidence actually covers

What is behind Semax is easy to overstate, because it is easy to skim past the difference between "studied in brain injury" and "studied in concussion."

The record is Russian, clinical, and built around stroke and cerebrovascular disease rather than sports or blast concussions. A study of acute ischemic stroke patients found improved neurological recovery at 12 to 18 mg per day of Semax, and a later trial found the same dosing range raised plasma BDNF and improved motor recovery and functional outcomes over a 20-day course. A separate study in patients with chronic cerebrovascular insufficiency, essentially reduced blood flow to the brain over time rather than a single acute event, found that Semax stabilized progression and reduced the risk of a subsequent stroke or TIA. None of these patients had a concussion. What they had in common with a concussion patient is a brain trying to repair itself under inflammatory and vascular stress, which is the process Semax's BDNF mechanism is actually built to support.

Nobody has run the concussion-specific trial. What we have instead is a compound with a real neurotrophic mechanism, a long safety record in a related injury population, and a growing body of connectivity data that happens to touch the exact networks concussion disrupts. That is a reasonable case for trying it, well short of proof that it works for this specific use.

The real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

One detail that actually matters here: route changes what Semax does. A route-comparison study found that intranasal Semax produces predominantly nootropic effects, while injectable Semax shifts toward an anxiolytic effect profile. If you want the focus and cognitive-recovery angle that the brain-injury literature is built on, intranasal is the route that record actually supports.

The Russian clinical dosing in the stroke studies above was 12 to 18 mg per day, delivered in a hospital setting. That is a different world from what people actually run at home. The dose the practitioner and peptide-user community has converged on for cognitive and recovery use is 300 to 600 mcg per day intranasally, split into two or three sprays, with some practitioners going up to 1,000 to 1,200 mcg per day for a short acute window of 7 to 14 days when the goal is neuroprotection rather than daily maintenance. Morning and early afternoon dosing works better than evening, since Semax has an activating effect that can get in the way of falling asleep, and sleep is doing at least as much of the repair work here as anything you inject or spray.

For a physician-prescribed route, see OHM's telehealth page; for research-use-only sourcing and OHM's vendor disclosures, see Where to buy.

Where this fits in an actual recovery

A peptide is one lever, and it is rarely the first one people should reach for. If you want a broader read on what the evidence does and does not support for a compound like this, our piece on Semax and anxiety without sedation goes deeper into the connectivity data. For post-concussion recovery specifically, the foundation is still graded return to light and activity, real sleep, and hydration, and, if symptoms are dragging past a month or two, a clinician who actually treats concussions for a living. Semax sits on top of that work.

The mechanism is real, the brain-injury record behind it is real, and the concussion-specific trial simply does not exist yet. People are still trying it anyway, because the neuroplasticity case is strong enough to be worth testing once the acute injury has settled and a clinician is in the loop. Where the evidence actually lands, right now, is somewhere between "mechanistically promising" and "proven for this exact use," and that gap is worth knowing about before you spend money closing it.